Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie til at lære om undersøgelsesmedicinen PF-08634404 i kombination med kemoterapi ved gastroøsofageal cancer

9. oktober 2026 opdateret af: Pfizer

EN FASE 2/3 INTERVENTIONEL UNDERSØGELSE AF PF-08634404 I KOMBINATION MED KEMOTERAPI BEHANDLINGSNAIVE DELTAGERE MED LOKALT FREMSKREDEN ELLER METASTATISK MAVE-, GASTROESOFAGEAL KRYDS ELLER SPISERØRSADENOKARCINOM

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.

The study has two parts:

  • In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
  • In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.

The treatment will be given in repeated time periods called cycles.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

840

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Ikke rekrutterer endnu
        • London Health Sciences Centre - Verspeeten Family Cancer Centre
    • California
      • Atascadero, California, Forenede Stater, 93422
        • Rekruttering
        • UCLA Hematology/Oncology - Atascadero
      • Burbank, California, Forenede Stater, 91505
        • Rekruttering
        • UCLA Hematology/Oncology - Burbank
      • Encino, California, Forenede Stater, 91436
        • Rekruttering
        • UCLA Hematology/Oncology - Encino
      • Marina del Rey, California, Forenede Stater, 90292
        • Rekruttering
        • UCLA Hematology/Oncology - Marina del Rey
      • Porter Ranch, California, Forenede Stater, 91326
        • Rekruttering
        • UCLA Hematology/Oncology - Porter Ranch
      • San Francisco, California, Forenede Stater, 94158
        • Ikke rekrutterer endnu
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • San Francisco, California, Forenede Stater, 94158
        • Ikke rekrutterer endnu
        • UCSF Investigational Drugs Pharmacy
      • San Luis Obispo, California, Forenede Stater, 93401
        • Rekruttering
        • UCLA Hematology/Oncology - San Luis Obispo
      • Santa Barbara, California, Forenede Stater, 93101
        • Rekruttering
        • UCLA Hematology/Oncology - Santa Barbara
      • Santa Monica, California, Forenede Stater, 90404
        • Rekruttering
        • UCLA Hematology/Oncology - Santa Monica
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Boulder, Colorado, Forenede Stater, 80303
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Centennial, Colorado, Forenede Stater, 80112
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Forenede Stater, 80907
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Forenede Stater, 80923
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Forenede Stater, 80220
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Englewood, Colorado, Forenede Stater, 80113
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Lakewood, Colorado, Forenede Stater, 80228
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Littleton, Colorado, Forenede Stater, 80120
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Lone Tree, Colorado, Forenede Stater, 80124
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Longmont, Colorado, Forenede Stater, 80504
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Pueblo, Colorado, Forenede Stater, 81003
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
      • Thornton, Colorado, Forenede Stater, 80260
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP
    • Florida
      • Daytona Beach, Florida, Forenede Stater, 32117
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
      • Fleming Island, Florida, Forenede Stater, 32003
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
      • Palm Beach Gardens, Florida, Forenede Stater, 33410
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
      • Sebring, Florida, Forenede Stater, 33870
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
      • Wellington, Florida, Forenede Stater, 33414
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
      • West Palm Beach, Florida, Forenede Stater, 33401
        • Ikke rekrutterer endnu
        • Florida Cancer Specialists
    • Illinois
      • Arlington Heights, Illinois, Forenede Stater, 60005
        • Rekruttering
        • Illinois Cancer Specialists
      • Bloomington, Illinois, Forenede Stater, 61704
        • Rekruttering
        • Illinois CancerCare - Bloomington
      • Chicago, Illinois, Forenede Stater, 60631
        • Rekruttering
        • Illinois Cancer Specialists
      • Galesburg, Illinois, Forenede Stater, 61401
        • Rekruttering
        • Illinois CancerCare - Galesburg
      • Niles, Illinois, Forenede Stater, 60714
        • Rekruttering
        • Illinois Cancer Specialists
      • Ottawa, Illinois, Forenede Stater, 61350
        • Rekruttering
        • Illinois CancerCare-Ottawa-Fox River Cancer Center
      • Pekin, Illinois, Forenede Stater, 61554
        • Rekruttering
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Forenede Stater, 61615
        • Rekruttering
        • Illinois CancerCare, P.C.
      • Peru, Illinois, Forenede Stater, 61354
        • Rekruttering
        • Illinois CancerCare-Peru - Valley Regional Cancer Center
      • Washington, Illinois, Forenede Stater, 61571
        • Rekruttering
        • Illinois CancerCare-Washington
    • Maryland
      • Annapolis, Maryland, Forenede Stater, 21401
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Bethesda, Maryland, Forenede Stater, 20817
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Brandywine, Maryland, Forenede Stater, 20613
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Columbia, Maryland, Forenede Stater, 21044
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Germantown, Maryland, Forenede Stater, 20876
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Largo, Maryland, Forenede Stater, 20774
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Rockville, Maryland, Forenede Stater, 20850
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
      • Silver Spring, Maryland, Forenede Stater, 20904
        • Rekruttering
        • Maryland Oncology Hematology, P.A.
    • Nevada
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Health Medical Oncology
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Office of Clinical Research
    • New Jersey
      • Morristown, New Jersey, Forenede Stater, 07960
        • Ikke rekrutterer endnu
        • Atlantic Health System
      • Summit, New Jersey, Forenede Stater, 07901
        • Ikke rekrutterer endnu
        • Atlantic Health System / Overlook Medical Center
    • New York
      • Long Island City, New York, Forenede Stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
      • Long Island City, New York, Forenede Stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - Main Campus
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
      • New York, New York, Forenede Stater, 10022
        • Rekruttering
        • Rockefeller Outpatient Pavilion (53rd Street)
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45245
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Forenede Stater, 45242
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Forenede Stater, 45211
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
      • Fairfield, Ohio, Forenede Stater, 45014
        • Rekruttering
        • Oncology Hematology Care Clinical Trials, LLC
    • Pennsylvania
      • Bensalem, Pennsylvania, Forenede Stater, 19020
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Doylestown, Pennsylvania, Forenede Stater, 18901
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Horsham, Pennsylvania, Forenede Stater, 19044
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Langhorne, Pennsylvania, Forenede Stater, 19047
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Media, Pennsylvania, Forenede Stater, 19063
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Sellersville, Pennsylvania, Forenede Stater, 18960
        • Rekruttering
        • Alliance Cancer Specialists, PC
      • Wynnewood, Pennsylvania, Forenede Stater, 19096
        • Rekruttering
        • Alliance Cancer Specialists, PC
    • Texas
      • Irving, Texas, Forenede Stater, 75063
        • Rekruttering
        • US Oncology Investigational Products Center (IPC)
    • Virginia
      • Arlington, Virginia, Forenede Stater, 22201
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Chesapeake, Virginia, Forenede Stater, 23320
        • Rekruttering
        • Virginia Oncology Associates
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Hampton, Virginia, Forenede Stater, 23666
        • Rekruttering
        • Virginia Oncology Associates
      • Manassas, Virginia, Forenede Stater, 20110
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Newport News, Virginia, Forenede Stater, 23606
        • Rekruttering
        • Virginia Oncology Associates
      • Norfolk, Virginia, Forenede Stater, 23502
        • Rekruttering
        • Virginia Oncology Associates
      • Reston, Virginia, Forenede Stater, 20190
        • Rekruttering
        • Virginia Cancer Specialists, PC
      • Virginia Beach, Virginia, Forenede Stater, 23456
        • Rekruttering
        • Virginia Oncology Associates
      • Woodbridge, Virginia, Forenede Stater, 22191
        • Rekruttering
        • Virginia Cancer Specialists, PC
    • Washington
      • Seattle, Washington, Forenede Stater, 98195
        • Rekruttering
        • University of Washington Medical Center
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Harborview Medical Center
      • Paris, Frankrig, 75015
        • Rekruttering
        • Hôpital Européen Georges Pompidou
    • Central District
      • Petah Tikva, Central District, Israel, 4941492
        • Rekruttering
        • Rabin Medical Center
    • HA Merkaz
      • Ramat Gan, HA Merkaz, Israel, 5265601
        • Rekruttering
        • Sheba Medical Center
    • TELL ABĪB
      • Tel Aviv, TELL ABĪB, Israel, 6423906
        • Rekruttering
        • Sourasky Medical Center
      • Milan, Italien, 20141
        • Rekruttering
        • Istituto Europeo di Oncologia IRCCS
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510655
        • Rekruttering
        • The Sixth Affiliated hospital, Sun Yat-sen University
    • Hubei
      • Wuhan, Hubei, Kina, 430079
        • Rekruttering
        • Hubei Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200031
        • Rekruttering
        • Zhongshan Hospital,Fudan University
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Rekruttering
        • Sichuan Cancer hospital
      • Bayamón, Puerto Rico, 00959
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Bayamón Office
    • United States
      • Manati, United States, Puerto Rico, 00674
        • Rekruttering
        • Pan American Center for Oncology Trials, LLC - Manati Office
    • Barcelona [barcelona]
      • Barcelona, Barcelona [barcelona], Spanien, 08035
        • Rekruttering
        • Hospital Universitari Vall d'Hebron
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spanien, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
    • Ourense [orense]
      • Ourense, Ourense [orense], Spanien, 32005
        • Ikke rekrutterer endnu
        • Complexo Hospitalario Universitario de Ourense
      • Tainan, Taiwan, 704302
        • Rekruttering
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11217
        • Rekruttering
        • Taipei Veterans General Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
  • Evidence of locally advanced or metastatic disease.
  • Eastern Cooperative Oncology Group performance status (ECOG) 0-1
  • No prior systemic therapy for advanced or metastatic disease.
  • Adequate hepatic, liver, and renal function
  • HER-2 negative status based on local testing
  • PD-L1 positive status based on local testing

Exclusion Criteria:

  • Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
  • Clinically significant risk of hemorrhage or fistula
  • Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
  • Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
  • Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 2 Portion

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Andre navne:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Eksperimentel: Phase 3: Arm A

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Andre navne:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Aktiv komparator: Phase 3: Arm B

Nivolumab + Chemotherapy

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Participants will receive Nivolumab intravenously.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator.

Approximately 4 years
Phase 2: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: Overall Survival (OS)
Tidsramme: Approximately 4 years

OS is defined as the time from the date of randomization to the date of death due to any cause.

Approximately 4 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Fase 2: Forekomst af anti-lægemiddel-antistof (ADA) mod PF-08634404
Tidsramme: Ca. 21 måneder
Ca. 21 måneder
Fase 3: Forekomst af ADA mod PF-08634404
Tidsramme: Cirka 21 måneder
Cirka 21 måneder
Fase 3: Ændring fra baseline i Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) Total score
Tidsramme: Ca. 4 år
Ca. 4 år
Fase 3: Tid til definitiv forværring i FACT-Ga Total score
Tidsramme: Cirka 4 år
Cirka 4 år
Fase 3: Tid til definitiv forringelse i Gastric Cancer Subscale (GaCS)-score
Tidsramme: Cirka 4 år
Cirka 4 år
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Overall Survival (OS)
Tidsramme: Approximately 4 years

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 4 years
Phase 2: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 2: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR.

Approximately 4 years
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator.

Approximately 4 years
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Tidsramme: Approximately 4 years

PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s)

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. maj 2026

Primær færdiggørelse (Anslået)

22. juli 2031

Studieafslutning (Anslået)

21. juli 2032

Datoer for studieregistrering

Først indsendt

30. januar 2026

Først indsendt, der opfyldte QC-kriterier

30. januar 2026

Først opslået (Faktiske)

6. februar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C6461016
  • 2025-524717-86-00 (Registry Identifier: CTIS (EU))
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .